argenx to host conference call & webcast to report second quarter business update and half year 2018 financial results on August 2, 2018

 

argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced it will host a conference call and audio webcast on Thursday, August 2, 2018 at 3:00 p.m. CEST (9:00 a.m. EDT) to discuss financial results for the first half of 2018 and to provide a second quarter business update.

To participate in the conference call, please select your phone number below, and use the confirmation code 7669735. The webcast may be accessed on the homepage of the argenx website at www.argenx.com or by clicking here.

 

Dial-in numbers:

Please dial in 5-10 minutes prior to 3 p.m. CET/ 9 a.m. EDT using the number and conference ID below.

 

Confirmation Code: 7669735

 

United Kingdom:                                              +44 330 336 9411

National free phone - United Kingdom:                0800 279 7204

USA:                                                                       +1 929 477 0448

National free phone - USA:                        888 599 8686

France:                                                                                 +33 1 76 77 22 57

National free phone - France:                    0805 101 278

Belgium:                                                              +32 2 400 6926

National free phone - Belgium:                  0800 38625

Netherlands:                                                     +31 20 703 8261

National free phone - Netherlands:         0800 265 9169

 

A question and answer session will follow the presentation of the results. Go to www.argenx.com to access the live audio webcast. The archived webcast will also be available (90 days) for replay shortly after the close of the call from the "Downloads" section of the argenx website.

Note

argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe auto-immune diseases and cancer. The company is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. argenx's ability to execute on this focus is enabled by its suite of differentiated technologies. The SIMPLE AntibodyTM Platform, based on the powerful llama immune system, allows argenx to exploit novel and complex targets, and the three antibody engineering technologies are designed to enable expansion of the therapeutic index of the company's product candidates.
www.argenx.com

 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?